IAS 2023 | Short-course tuberculosis (TB) preventive treatment does not affect the virologic efficacy of INSTIs in treating HIV
People Living With HIV (PLWH) are at high risk of active tuberculosis (TB). Guidelines both domestically and internationally suggest that PLWH with positive latent tuberculosis infection (LTBI) screening and those with a history of close contact with active TB should receive TB preventive treatment. However, commonly used preventive treatment regimens such as rifampin and rifapentine have potential drug interactions with HIV antiretroviral therapy (ART). A multi-center retrospective study from Taiwan, China, presented at the 12th International AIDS Society HIV Science Conference (IAS 2023) showed that ART based on integrase inhibitors (INSTIs) combined with rifapentine-based short-course TB preventive treatment does not affect the patient's sustained HIV virologic suppression rate.
